Yüklüyor......
P07.02 Trials of a personalized peptide vaccine (ITK-1) for patients with recurrent or progressive glioblastoma (GBM)
Immunotherapy trials for glioblastoma (GBM) have some effects but the efficacy was limited, some because of the low immunogenicity and diverse antigens for GBMs. Personalized selection of suitable peptides for patients is one way to conquer this problem. We conducted serial series of clinical trials...
Kaydedildi:
| Yayımlandı: | Neuro Oncol |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Oxford University Press
2017
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5464231/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox036.187 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|